Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro
LEVERKUSEN, Germany (Reuters) - Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion).
The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.
Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.
(Reporting by Frank Siebelt; Writing by Ludwig Burger)
- Tweet this
- Share this
- Digg this
DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.
Trending On Reuters
Worldwide child deaths will be halved over the next 15 years, polio, guinea worm and river blindness will be eradicated, and there will be a single-dose cure for malaria. Full Article